Another finding in our cohort is the high frequency of co-alterations in RET fusion-positive NSCLC, with 9% of cases diagnosed concurrently with EGFR, KRAS, and ALK alterations, which highlights the need for comprehensive genomic profiling even if such a more frequent alteration is identified, not to miss a RET fusion leading to potential eligibility to RET inhibitors; in our cohort, these patients had sustained response to pralsetinib. This evidence concerns the gene RET and non-small cell lung carcinoma.